391 related articles for article (PubMed ID: 22374260)
1. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
2. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Pascual D; Goicoechea C; Suardíaz M; Martín MI
Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases.
Paszcuk AF; Dutra RC; da Silva KA; Quintão NL; Campos MM; Calixto JB
PLoS One; 2011; 6(9):e24034. PubMed ID: 21931637
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.
Ledeboer A; Jekich BM; Sloane EM; Mahoney JH; Langer SJ; Milligan ED; Martin D; Maier SF; Johnson KW; Leinwand LA; Chavez RA; Watkins LR
Brain Behav Immun; 2007 Jul; 21(5):686-98. PubMed ID: 17174526
[TBL] [Abstract][Full Text] [Related]
5. Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Segat GC; Manjavachi MN; Matias DO; Passos GF; Freitas CS; Costa R; Calixto JB
Neuropharmacology; 2017 Oct; 125():207-219. PubMed ID: 28729222
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
7. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
Naguib M; Xu JJ; Diaz P; Brown DL; Cogdell D; Bie B; Hu J; Craig S; Hittelman WN
Anesth Analg; 2012 May; 114(5):1104-20. PubMed ID: 22392969
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
9. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
Zhu CZ; Mikusa JP; Fan Y; Hollingsworth PR; Pai M; Chandran P; Daza AV; Yao BB; Dart MJ; Meyer MD; Decker MW; Hsieh GC; Honore P
Br J Pharmacol; 2009 Jun; 157(4):645-55. PubMed ID: 19371344
[TBL] [Abstract][Full Text] [Related]
10. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
11. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat.
Vera G; Chiarlone A; Cabezos PA; Pascual D; Martín MI; Abalo R
Life Sci; 2007 Jul; 81(6):468-79. PubMed ID: 17673260
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
13. Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy.
Xu JJ; Diaz P; Bie B; Astruc-Diaz F; Wu J; Yang H; Brown DL; Naguib M
Neuroscience; 2014 Feb; 260():185-94. PubMed ID: 24361916
[TBL] [Abstract][Full Text] [Related]
14. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
15. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
16. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats.
Ulugol A; Karadag HC; Ipci Y; Tamer M; Dokmeci I
Neurosci Lett; 2004 Nov; 371(2-3):167-70. PubMed ID: 15519750
[TBL] [Abstract][Full Text] [Related]
17. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
18. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
19. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
20. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
